Detailed price information for Boston Scientific Corp (BSX-N) from The Globe and Mail including charting and trades.

SAN FRANCISCO -- Surprisingly, a course of direct oral anticoagulation (DOAC) may be the safer choice for antithrombotic treatment after left atrial appendage (LAA) occlusion, according to the ANDES ...

Columbus Regional Health Heart & Vascular announced that its cardiovascular services team recently completed its 100th ...

Registry analysis suggests endoscopic lung volume reduction yields similar physiologic gains across sexes, but women report ...

Boston Scientific (BSX) announced an update on their ongoing clinical study.Claim 50% Off TipRanks Premium and Invest with Confidence Unlock hedge-fund level data and powerful investing tools ...

Abbott will soon enter the competitive U.S. pulsed field ablation (PFA) market, having just received FDA approval for its ...

A recent editorial article emphasized that the updated 2023 and 2024 guidelines for Atrial Fibrillation (AF) provide major ...

BMY has agreed to supply Eliquis free of charge to Medicaid starting in 2026 and will also donate seven tons of the active pharmaceutical ingredient used in Eliquis.

Abbott Laboratories is set to roll out its Volt PFA System in the U.S., following federal approval, and continue expanding ...

Boston Scientific Corporation is rated a Hold with double-digit revenue growth and margin expansion. Learn more about BSX ...

Introduction Atrial fibrillation (AF) is the leading cause of cardioembolic stroke and is associated with increased stroke severity and fatality. Early identification of AF is essential for adequate ...

MYQORZO, a Cardiac Myosin Inhibitor, Directly Addresses Underlying Hypercontractility Associated with Obstructive HCM ...